Acadian Asset Management LLC Takes $152,000 Position in XOMA Co. (XOMA)
Acadian Asset Management LLC bought a new position in shares of XOMA Co. (NASDAQ:XOMA) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 4,264 shares of the biotechnology company’s stock, valued at approximately $152,000. Acadian Asset Management LLC owned 0.05% of XOMA at the end of the most recent reporting period.
A number of other large investors have also bought and sold shares of XOMA. EAM Investors LLC acquired a new stake in XOMA during the 3rd quarter worth approximately $835,000. OxFORD Asset Management LLP acquired a new position in shares of XOMA in the 3rd quarter worth approximately $543,000. Finally, Bank of Montreal Can acquired a new position in shares of XOMA in the 4th quarter worth approximately $138,000. Institutional investors and hedge funds own 33.78% of the company’s stock.
A number of research analysts have recently issued reports on XOMA shares. Zacks Investment Research upgraded shares of XOMA from a “hold” rating to a “strong-buy” rating and set a $33.00 price target on the stock in a research report on Friday, November 10th. HC Wainwright restated a “buy” rating and issued a $38.00 price target on shares of XOMA in a research report on Tuesday, November 7th. Wedbush restated a “buy” rating and issued a $33.00 price target on shares of XOMA in a research report on Tuesday, December 19th. Finally, TheStreet upgraded shares of XOMA from an “e+” rating to a “c-” rating in a research report on Wednesday, November 29th. One research analyst has rated the stock with a sell rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $38.33.
XOMA (NASDAQ:XOMA) last released its earnings results on Monday, November 6th. The biotechnology company reported $1.98 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $2.79. XOMA had a negative net margin of 3.51% and a negative return on equity of 1.14%. The company had revenue of $36.18 million for the quarter, compared to the consensus estimate of $17.95 million. research analysts expect that XOMA Co. will post -0.08 earnings per share for the current fiscal year.
In other XOMA news, SVP Thomas M. Burns sold 22,222 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $28.69, for a total transaction of $637,549.18. Following the completion of the sale, the senior vice president now owns 13,538 shares in the company, valued at approximately $388,405.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Thomas M. Burns sold 6,983 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $30.99, for a total transaction of $216,403.17. Following the sale, the chief financial officer now owns 13,538 shares of the company’s stock, valued at approximately $419,542.62. The disclosure for this sale can be found here. Insiders have sold a total of 87,069 shares of company stock worth $2,517,993 in the last quarter. 3.02% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Acadian Asset Management LLC Takes $152,000 Position in XOMA Co. (XOMA)” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://theolympiareport.com/2018/02/08/acadian-asset-management-llc-takes-152000-position-in-xoma-co-xoma.html.
XOMA Company Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Want to see what other hedge funds are holding XOMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for XOMA Co. (NASDAQ:XOMA).
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.